ArticleBreast cancer research and treatment2009
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
Article in Breast cancer research and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Adherence to oral antineoplastic agents, an overview and meta-analysis.The oncologist · 2026Pooled it
- Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- A Systematic Review of Adherence to Oral Antineoplastic Therapies.The oncologist · 2016Pooled it
- Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).Annals of oncology : official journal of the European Society for Medical Oncology · 2012Trial
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Optimistic Bias and Personality Factors in Adherence to Oral Anticancer Treatments in Metastatic Breast Cancer: A Retrospective Analysis of Data From a Randomized Controlled Trial.Cancer control : journal of the Moffitt Cancer CenterTrial
- Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- A Machine Learning Model to Predict Patients' Adherence Behavior and a Decision Support System for Patients With Metastatic Breast Cancer: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2023Article
- Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial.Cancer medicine · 2021Article
- ATF3-Induced Mammary Tumors Exhibit Molecular Features of Human Basal-Like Breast Cancer.International journal of molecular sciences · 2021Article
- Patient-Oncologist Communication Regarding Oral Chemotherapy During Routine Office Visits.JCO oncology practice · 2020Article
- Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center.Patient preference and adherence · 2018Article
- Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.Frontiers in pharmacology · 2016Article
- Oral antineoplastic agents: how do we care about adherence?British journal of clinical pharmacology · 2015Review
- Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.BMC research notes · 2015Article
- Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.Oncoimmunology · 2015Article
- Oral anticancer agent medication adherence by outpatients.Oncology letters · 2014Article
- Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer.American health & drug benefits · 2014Article
- Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.BMJ open · 2013Article
- Treatment of HER2-positive breast cancer: current status and future perspectives.Nature reviews. Clinical oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThis phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC).
methodsSequential cohorts (n = 3) received G and escalating C on a 14 day on/7 day off schedule, with a validation cohort (n = 10) at the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) was defined in cycle 1. The primary endpoint was safety; secondary endpoints included response and adherence.
resultsAbout 19 patients were treated for a median of 5 cycles. No patients in sequential cohorts experienced DLT; C MTD was 2,000 mg/m(2)/day when paired with daily G 250 mg. In the validation cohort, four experienced serious toxicities, including diarrhea, mucositis, and palmarplantar dysesthesia. At the MTD, 6 (46%) required a C dose reduction, and 3 (23%) came off study for toxicity. One partial response was observed (8%, 95% CI 0.2-38.5%); five had stable disease >24 weeks (26, 95% CI 9-51%). Patients missed few drug doses, with the suggestion of overadherence to therapy.
conclusionsIn this phase I study of G and C in MBC, a C MTD was identified, and significant toxicity was observed. About 8% demonstrated a response, with 26% maintaining stable disease. The possibility of overadherence, as suggested in this study, may have implications for other trials of oral antineoplastic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.